Table 1.
Demographic data, stage, primary tumor histology and type of first CPI treatment
| All patients (n = 428) |
Ongoing CR (n = 77) |
Died < 6 months (n = 69) |
No local therapy** (n = 230) |
NED or NPRD (n = 52) |
|
|---|---|---|---|---|---|
| Median age (IQR) | 65 (55 – 74) | 68 (55 – 75) | 65 (58 – 74) | 64 (55 – 74) | 61 (54 – 70) |
| Gender | 63% male | 68% male | 67% male | 61% male | 62% male |
|
Stage before CPI Stage M1a (%) Stage M1b (%) Stage M1c (%) Stage M1d (%) |
99 (23%) 90 (21%) 152 (36%) 87 (20%) |
22 (29%) 21 (27%) 31 (40%) 3 (4%) |
11 (16%) 8 (12%) 36 (52%) 14 (20%) |
55 (24%) 53 (23%) 69 (30%) 53 (23%) |
11 (21%) 8 (15%) 16 (31%) 17 (33%) |
| Sun-shielded* | 93 (22%) | 5 (6%) | 19 (28%) | 54 (23%) | 15 (29%) |
|
1st Therapy (%) CTLA4 PD1 or PDL1 CTLA4 + PD1 |
124 (29%) 129 (30%) 175 (41%) |
11 (14%) 23 (30%) 43 (56%) |
28 (41%) 23 (33%) 18 (26%) |
69 (30%) 71 (31%) 90 (39%) |
16 (31%) 12 (23%) 24 (46%) |
Abbreviations: CR = complete response; IQR = interquartile range; NED = no evidence of disease; NPRD = non-progressive residual disease
Stage M1a = distant metastases to skin or lymph nodes. Stage M1b = metastases to lung with or without M1a metastases. Stage M1c = metastases to visceral sites with or without M1a or M1b. Stage M1d = metastases to CNS with or without extra-cranial metastasis [20]
*Sun-shielded melanomas include mucosal, ocular, perineal, and acral lentiginous
**Some patients had procedures that did not meet inclusion criteria